Recent Updates — COYA
Coya Therapeutics announced the initiation of an open-label extension for its Phase 2/3 ALSTARS Trial evaluating COYA 302 in amyotrophic lateral sclerosis (ALS), expected to begin in November 2026. To prioritize resources toward this ALS development, the company delayed the planned start of a Phase 2 clinical trial for frontotemporal dementia (FTD) from late 2026 to 2027. The firm maintains its cash runway guidance, expecting existing funds to support operations into the second half of 2027, beyond the anticipated ALSTARS topline data readout. Coya Therapeutics is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases.
Coya Therapeutics, Inc. has completed enrollment of the planned 120 patients in its ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The double-blind study randomizes subjects to receive dosing regimens of the company's proprietary low-dose IL-2 and CTLA-4 Ig combination or placebo. Topline data from the treatment phase are anticipated in early Q2 2027. Coya Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for neurological diseases.
Coya Therapeutics announced that the 100th patient has been enrolled in its Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for amyotrophic lateral sclerosis. The company anticipates completing full enrollment of 120 participants to permit reporting top-line data in early Q2 2027. Coya Therapeutics operates in the biotechnology industry, developing immunotherapies for neurological diseases.
Coya Therapeutics reported financial results for the quarter ended June 30, 2026. The company held $43.2 million in cash and incurred a net loss of $6.6 million, with research and development expenses rising to $5.0 million due to clinical trial advancements. General and administrative costs decreased by $0.6 million to $2.3 million. The firm raised approximately $10.95 million through an ATM offering program. Clinically, Coya received FDA Fast Track Designation for its lead candidate COYA 302 in ALS, initiated a Phase 2 study in frontotemporal dementia (FTD), and plans to complete ALSTARS trial enrollment by the end of 2026 with top-line data expected in Q1 2027. Coya Therapeutics is a clinical-stage biotechnology company developing biologics intended to enhance T-cell function in patients with neurodegenerative disorders.